Biofarm (BSE:BIO) Debt-to-Asset : 0.00 (As of Mar. 2025)

View and export this data going back to 1996. Start your Free Trial

What is Biofarm Debt-to-Asset?

Biofarm's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was lei0.0 Mil. Biofarm's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2025 was lei1.0 Mil. Biofarm's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2025 was lei589.4 Mil. Biofarm's debt to asset for the quarter that ended in Mar. 2025 was 0.00.

Biofarm Debt-to-Asset Historical Data

The historical data trend for Biofarm's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biofarm Debt-to-Asset Chart

Biofarm Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Asset

Get a 7-Day Free Trial

Biofarm Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Debt-to-Asset	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Biofarm's Debt-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Biofarm's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biofarm's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biofarm's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Biofarm's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

Biofarm Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Biofarm's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	1.013)	/	555.481
	=	0.00

Biofarm's Debt-to-Asset for the quarter that ended in Mar. 2025 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	1.013)	/	589.375
	=	0.00

Biofarm (BSE:BIO) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Biofarm Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Biofarm's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Biofarm Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biofarm SA (BSE:BIO) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

99 Logofatul Tautu Street, Sector 3, Bucharest, ROU, 031212

Website

https://www.biofarm.ro

Biofarm SA is a company engaged in production and marketing in the pharmaceutical sector. It is involved in the manufacture and wholesale of over-the-counter drugs, prescription medications, and dietary supplements. The firm's product portfolio includes pharmaceutical preparations for the digestive system, musculoskeletal system, immune stimulation, respiratory system, cold & flu symptoms, and venous circulation improvement, as well as multivitamins, antioxidants, antiseptics, disinfectants, and cosmetics, among others. Some of its brands are Triferment, Colebil, Cavit, Anghirol, Clorocalcin, and Bixtonim. Additionally, the company offers services, such as investment in research, promotion, and packaging.